EP1876893A4 - Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase - Google Patents
Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomeraseInfo
- Publication number
- EP1876893A4 EP1876893A4 EP06750227A EP06750227A EP1876893A4 EP 1876893 A4 EP1876893 A4 EP 1876893A4 EP 06750227 A EP06750227 A EP 06750227A EP 06750227 A EP06750227 A EP 06750227A EP 1876893 A4 EP1876893 A4 EP 1876893A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- proteasome
- cancer treatment
- combined inhibition
- telomerase
- telomerase activities
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title 1
- 108010017842 Telomerase Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 2
- 229940123582 Telomerase inhibitor Drugs 0.000 abstract 2
- 239000003207 proteasome inhibitor Substances 0.000 abstract 2
- 239000003277 telomerase inhibitor Substances 0.000 abstract 2
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002301 combined effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000005713 exacerbation Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67163005P | 2005-04-15 | 2005-04-15 | |
PCT/US2006/014137 WO2006113470A2 (fr) | 2005-04-15 | 2006-04-14 | Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1876893A2 EP1876893A2 (fr) | 2008-01-16 |
EP1876893A4 true EP1876893A4 (fr) | 2010-09-01 |
EP1876893B1 EP1876893B1 (fr) | 2012-04-11 |
Family
ID=37115747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06750227A Active EP1876893B1 (fr) | 2005-04-15 | 2006-04-14 | Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase |
Country Status (4)
Country | Link |
---|---|
US (1) | US7998938B2 (fr) |
EP (1) | EP1876893B1 (fr) |
AT (1) | ATE553198T1 (fr) |
WO (1) | WO2006113470A2 (fr) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1585974B1 (fr) | 2003-01-24 | 2013-02-27 | University of Utah | Procedes permettant de predire le risque de mortalite en mesurant la longueur des telomeres |
AU2004271215B2 (en) | 2003-09-09 | 2009-07-16 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
CA2613889A1 (fr) | 2005-06-08 | 2006-12-14 | Centocor, Inc. | Therapie cellulaire pour la degenerescence oculaire |
PL2623113T3 (pl) | 2005-11-09 | 2018-05-30 | Onyx Therapeutics, Inc. | Związek do hamowania enzymu |
WO2007127163A2 (fr) * | 2006-04-24 | 2007-11-08 | Geron Corporation | Méthode et composition pour le traitement d'une tumeur du snc |
US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
DK2041158T3 (da) | 2006-06-19 | 2013-06-24 | Onyx Therapeutics Inc | Peptid-epoxidketoner til proteasom inhibering |
ES2696828T3 (es) | 2006-10-30 | 2019-01-18 | Geron Corp | Inhibidor de telomerasa y gemcitabina combinados para el tratamiento del cáncer |
EP2134364B1 (fr) * | 2007-03-09 | 2013-02-13 | Geron Corporation | Traitement de carcinomes avec une combinaison d'inhibiteurs de voie egf et de telomerase |
US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
KR101617243B1 (ko) | 2007-07-31 | 2016-05-02 | 라이프스캔, 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
KR20170125413A (ko) | 2007-10-04 | 2017-11-14 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
US8377992B2 (en) | 2007-10-22 | 2013-02-19 | The Wistar Institute | TRBD-binding effectors and methods for using the same to modulate telomerase activity |
KR101592182B1 (ko) | 2007-11-27 | 2016-02-05 | 라이프스캔, 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
KR101731474B1 (ko) | 2008-02-21 | 2017-05-11 | 얀센 바이오테크 인코포레이티드 | 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물 |
PL2942392T3 (pl) | 2008-06-30 | 2019-02-28 | Janssen Biotech, Inc | Różnicowanie pluripotencjalnych komórek macierzystych |
WO2010048298A1 (fr) | 2008-10-21 | 2010-04-29 | Proteolix, Inc. | Thérapie de combinaison avec des peptides époxycétones |
US9234178B2 (en) | 2008-10-31 | 2016-01-12 | Janssen Biotech, Inc. | Differentiation of human pluripotent stem cells |
CN102333862B (zh) | 2008-10-31 | 2018-04-27 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌谱系的分化 |
AU2009316580B2 (en) | 2008-11-20 | 2016-04-14 | Janssen Biotech, Inc. | Pluripotent stem cell culture on micro-carriers |
JP5719305B2 (ja) | 2008-11-20 | 2015-05-13 | ヤンセン バイオテツク,インコーポレーテツド | 平面支持体上での細胞付着及び培養のための方法及び組成物 |
US9689028B2 (en) | 2008-12-22 | 2017-06-27 | University Of Utah Foundation | Monochrome multiplex quantitative PCR |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
MX340952B (es) | 2009-07-20 | 2016-07-29 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionarias humanas. |
RU2540016C2 (ru) | 2009-07-20 | 2015-01-27 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека |
WO2011011300A2 (fr) | 2009-07-20 | 2011-01-27 | Centocor Ortho Biotech Inc. | Différentiation de cellules souches embryonnaires humaines |
EP2519231B1 (fr) | 2009-10-01 | 2017-03-15 | Janssen Pharmaceutica NV | Traitement du cancer par des inhibiteurs du protéasome |
US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
US9150833B2 (en) | 2009-12-23 | 2015-10-06 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
SG181685A1 (en) | 2009-12-23 | 2012-07-30 | Centocor Ortho Biotech Inc | Differentiation of human embryonic stem cells |
RU2607380C2 (ru) | 2010-03-01 | 2017-01-10 | Янссен Байотек, Инк. | Способы очистки клеток, производных от плюрипотентных стволовых клеток |
US9359398B2 (en) | 2010-03-01 | 2016-06-07 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
WO2011143299A2 (fr) | 2010-05-12 | 2011-11-17 | Centocor Ortho Biotech Inc. | Différentiation de cellules souches embryonnaires humaines |
US9506036B2 (en) | 2010-08-31 | 2016-11-29 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
MX348537B (es) | 2010-08-31 | 2017-06-07 | Janssen Biotech Inc | Diferencia de celulas madre pluripotentes. |
EP3211070A1 (fr) | 2010-08-31 | 2017-08-30 | Janssen Biotech, Inc. | Différenciation de cellules souches embryonnaires humaines |
RU2705001C2 (ru) | 2011-12-22 | 2019-11-01 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки |
CN104160018A (zh) | 2012-03-07 | 2014-11-19 | 詹森生物科技公司 | 用于扩增和维持多能干细胞的成分确定的培养基 |
ES2690118T3 (es) | 2012-06-08 | 2018-11-19 | Janssen Biotech, Inc. | Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas |
WO2014011695A2 (fr) | 2012-07-09 | 2014-01-16 | Onyx Therapeutics, Inc. | Promédicaments d'inhibiteurs d'époxy cétone protéase peptidique |
US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
CA2892445C (fr) * | 2012-11-30 | 2022-06-28 | Geron Corporation | Marqueurs de diagnostic pour le traitement de troubles de la proliferation cellulaire par des inhibiteurs de telomerase |
US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
DK3456333T3 (da) | 2012-12-07 | 2020-05-18 | Geron Corp | Anvendelse af telomeraseinhibitor imetelstat til behandling af myelodysplastisk syndrom |
CA2896750A1 (fr) | 2012-12-31 | 2014-07-03 | Janssen Biotech, Inc. | Mise en suspension et agregation de cellules pluripotentes humaines pour la differenciation en cellules endocrines du pancreas |
KR101942769B1 (ko) | 2012-12-31 | 2019-01-28 | 얀센 바이오테크 인코포레이티드 | Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화 |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
BR112015015770A2 (pt) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas |
ES2762860T3 (es) * | 2013-05-22 | 2020-05-26 | Telomere Diagnostics Inc | Medidas de abundancia de telómeros cortos |
US9708360B2 (en) * | 2013-09-30 | 2017-07-18 | Geron Corporation | Phosphorodiamidate backbone linkage for oligonucleotides |
JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
WO2015175307A1 (fr) | 2014-05-16 | 2015-11-19 | Janssen Biotech, Inc. | Utilisation de petites molécules pour améliorer l'expression du gène mafa dans des cellules endocrines pancréatiques |
JP2018501799A (ja) | 2014-12-30 | 2018-01-25 | テロメア ダイアグノスティクス インコーポレイテッド | マルチプレックス定量的pcr |
WO2017165675A1 (fr) * | 2016-03-24 | 2017-09-28 | The Board Of Regents Of The University Of Texas System | Traitement de maladies prolifératives résistantes aux médicaments au moyen de composés modifiant les télomères induits par la télomérase |
MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
EP3318276A1 (fr) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques |
WO2021257910A1 (fr) * | 2020-06-17 | 2021-12-23 | University Of Utah Research Foundation | Sélection de patient à base de biomarqueur de traitement par inhibiteur de protéasome |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
US5958680A (en) * | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
US5760062A (en) * | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
US6444650B1 (en) * | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
US6331399B1 (en) * | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
DK1644009T3 (en) | 2003-06-23 | 2018-03-05 | Telomerase Activation Sciences Inc | Compositions for increasing telomerase activity and treating HIV infection |
AU2004271215B2 (en) * | 2003-09-09 | 2009-07-16 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
-
2006
- 2006-04-14 WO PCT/US2006/014137 patent/WO2006113470A2/fr active Search and Examination
- 2006-04-14 US US11/918,581 patent/US7998938B2/en active Active
- 2006-04-14 EP EP06750227A patent/EP1876893B1/fr active Active
- 2006-04-14 AT AT06750227T patent/ATE553198T1/de active
Non-Patent Citations (1)
Title |
---|
ASAI AKIRA ET AL: "A novel telomerase template antagonist (GRN163) as a potential anticancer agent.", CANCER RESEARCH 15 JUL 2003 LNKD- PUBMED:12873987, vol. 63, no. 14, 15 July 2003 (2003-07-15), pages 3931 - 3939, XP002593248, ISSN: 0008-5472 * |
Also Published As
Publication number | Publication date |
---|---|
US20100010064A1 (en) | 2010-01-14 |
WO2006113470A2 (fr) | 2006-10-26 |
EP1876893A2 (fr) | 2008-01-16 |
US7998938B2 (en) | 2011-08-16 |
EP1876893B1 (fr) | 2012-04-11 |
WO2006113470A3 (fr) | 2006-12-14 |
ATE553198T1 (de) | 2012-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1876893A4 (fr) | Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase | |
WO2008054711A3 (fr) | Inhibiteur de télomérase combiné à la gemcitabine dans le traitement du cancer | |
MX2010006154A (es) | Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa. | |
SG164368A1 (en) | Treatment of cancer | |
MY163477A (en) | Pyrimidinyl-pyridazinone derivatives | |
MX2010005221A (es) | Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales. | |
MX2008016453A (es) | Composiciones y metodos para tratar infecciones parasitas. | |
SG157365A1 (en) | Compositions and methods for treating neoplastic diseases | |
AR048819A1 (es) | Metodos sinergicos y composiciones para el tratamiento del cancer | |
TWI367886B (en) | Proteasome inhibitors and methods of using the same | |
HK1130438A1 (en) | Using pi3k and mek modulators in treatments of cancer | |
WO2010148390A3 (fr) | Inhibiteurs du transport de la polyamine en tant que nouvelle thérapeutique | |
WO2011031474A3 (fr) | Utilisation de metformine dans le traitement et la prévention du cancer | |
TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
EA201391705A1 (ru) | Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i | |
WO2007002931A3 (fr) | Prodrogues d'alkylateur de phosphoramidate | |
TW200738263A (en) | ANG2 and VEGF inhibitor combinations | |
MX2009010930A (es) | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi3k alfa. | |
NZ577393A (en) | Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction | |
WO2008030883A3 (fr) | Traitement du cancer | |
WO2009074968A3 (fr) | Methode de prevision de l'efficacite d'un traitement anticancereux | |
WO2009114703A3 (fr) | Thérapie combinée pour le traitement d'un cancer | |
JO3262B1 (ar) | توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان | |
WO2006113426A3 (fr) | Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline | |
WO2006124904A3 (fr) | Traitement du cancer par inhibition combinee de telomerase et d'activites hsp90 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20071115 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MOORE, MALCOLM, A., S. Inventor name: CHIN, ALLISON, C. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100804 |
|
17Q | First examination report despatched |
Effective date: 20110321 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602006028791 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A01N0043040000 Ipc: C12N0015113000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/113 20100101AFI20110824BHEP Ipc: A01N 61/00 20060101ALI20110824BHEP Ipc: A61K 31/454 20060101ALI20110824BHEP Ipc: A01N 43/04 20060101ALI20110824BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 553198 Country of ref document: AT Kind code of ref document: T Effective date: 20120415 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602006028791 Country of ref document: DE Effective date: 20120606 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KIRKER & CIE S.A. |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 553198 Country of ref document: AT Kind code of ref document: T Effective date: 20120411 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20120411 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120811 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120813 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120430 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120712 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 |
|
26N | No opposition filed |
Effective date: 20130114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120722 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602006028791 Country of ref document: DE Effective date: 20130114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120711 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120414 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060414 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602006028791 Country of ref document: DE Representative=s name: BRINKMANN & PARTNER PATENTANWAELTE PARTNERSCHA, DE Ref country code: DE Ref legal event code: R082 Ref document number: 602006028791 Country of ref document: DE Representative=s name: RAUSCH WANISCHECK-BERGMANN BRINKMANN PARTNERSC, DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240312 Year of fee payment: 19 Ref country code: NL Payment date: 20240315 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240229 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240308 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240306 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240501 Year of fee payment: 19 |